Compare Crispr Therapeutics AG (CRSP) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Texas Instruments Incorporated — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while Texas Instruments Incorporated trades at $299.8 (market cap $278.08B). The key difference: Texas Instruments Incorporated is far larger — about 56× Crispr Therapeutics AG's market cap, and Texas Instruments Incorporated pays a 1.86% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TXN | |
|---|---|---|
Market Cap | $4.97B | $278.08B |
Sector | Health | Technology |
52-Week High | $76.78 | $332.35 |
52-Week Low | $44.34 | $153.33 |
Enterprise Value | $3.32B | $287.03B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Texas Instruments (TXN) trades at $298.57, down 4.15% over the past day, with technical indicators showing a bearish trend. The company reported mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with revenue of $17.68 billion in 2025. Analyst sentiment is positive, with a consensus price target of $317.20 and 48% buy ratings. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
Outlook: TXN benefits from AI infrastructure growth and operational leverage, but faces risks from high valuation multiples and competitive pressures. The stock offers potential upside to the consensus target, supported by solid profitability and dividend payments, though investors should monitor debt levels and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
